Prevention and treatment of Staphylococcus aureus pneumonia with a beta-cyclodextrin derivative
Brook E Ragle1, Vladimir A Karginov, Juliane Bubeck Wardenburg
1Department of Microbiology, University of Chicago, 920 E. 58th St., CLSC 607A, Chicago, IL 60637, USA.
Abstract:
Staphylococcus aureus pneumonia is a common, potentially life-threatening infection caused by this human pathogen. The only therapies available to treat S. aureus pneumonia are antibiotics, a modality that is jeopardized by the organism's remarkable ability to acquire antimicrobial resistance. S. aureus alpha-hemolysin is a pore-forming cytotoxin that is essential for the pathogenesis of pneumonia. Strains lacking this cytotoxin are avirulent in a murine model of pneumonia; likewise, vaccine-based strategies that antagonize the toxin afford protection against lethal disease. Disruption of the function of this toxin therefore provides a potent mechanism to prevent and/or treat S. aureus pneumonia. beta-Cyclodextrin derivatives are small molecules with a sevenfold symmetry that mirrors the heptameric alpha-hemolysin. These compounds block the assembled alpha-hemolysin pore, compromising toxin function. We report that a modified beta-cyclodextrin compound, IB201, prevents alpha-hemolysin-induced lysis of human alveolar epithelial cells. This protective effect does not result from the ability of the beta-cyclodextrin to impair formation of the oligomeric alpha-hemolysin on the cell surface, supporting a role for this molecule in blockade of the lytic pore. An examination of IB201 in murine S. aureus pneumonia demonstrated that administration of this compound prevents and treats disease, protecting against mortality. Consistent with the vital importance of alpha-hemolysin in pneumonia caused by methicillin-sensitive and highly virulent methicillin-resistant S. aureus strains, IB201 protects against lethal challenge with both types of isolates. These observations, coupled with a favorable safety profile of beta-cyclodextrin compounds, provide a novel strategy that may be developed to combat S. aureus pneumonia.
Insights
A novel beta-cyclodextrin compound, IB201, effectively blocks Staphylococcus aureus alpha-hemolysin, preventing and treating pneumonia. This offers a promising new strategy against antibiotic-resistant bacterial infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Staphylococcus aureus pneumonia is a life-threatening infection with limited treatment options due to antimicrobial resistance.
- Alpha-hemolysin, a toxin produced by S. aureus, is crucial for pneumonia development and represents a potential therapeutic target.
- Existing antibiotic treatments are threatened by the pathogen's ability to develop resistance.
Purpose of the Study:
- To investigate the potential of beta-cyclodextrin derivatives, specifically IB201, as a novel therapeutic strategy against S. aureus pneumonia.
- To determine if IB201 can block the function of S. aureus alpha-hemolysin and protect against pneumonia.
- To evaluate the efficacy of IB201 in both preventing and treating S. aureus pneumonia in a murine model.
Main Methods:
- Utilized a modified beta-cyclodextrin compound, IB201, designed to mimic the structure of alpha-hemolysin.
- Assessed IB201's ability to prevent alpha-hemolysin-induced lysis of human alveolar epithelial cells.
- Administered IB201 to a murine model of S. aureus pneumonia to evaluate its therapeutic and prophylactic effects against both methicillin-sensitive and methicillin-resistant strains.
Main Results:
- IB201 effectively prevented alpha-hemolysin-induced lysis of human alveolar epithelial cells, indicating pore blockade.
- IB201 demonstrated efficacy in preventing and treating S. aureus pneumonia in mice, significantly reducing mortality.
- The compound provided protection against lethal challenge with both methicillin-sensitive and methicillin-resistant S. aureus strains.
Conclusions:
- IB201 represents a novel therapeutic strategy for combating S. aureus pneumonia by targeting the essential alpha-hemolysin toxin.
- The compound's mechanism involves blocking the alpha-hemolysin pore, thereby disrupting its cytotoxic function.
- IB201 shows promise as a safe and effective treatment for S. aureus pneumonia, including infections caused by antibiotic-resistant strains.
More Related Videos
10:26P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
Published on: June 15, 2020
07:25Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients
Published on: July 16, 2020
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:14Atypical Pneumonia
01:24Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:25Clinical Significance of Antibiotic Resistance